Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
376
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Efficacy of adjunctive ambrisentan treatment for digital ulcers in patients with systemic sclerosis: a case series study

Ambrisentan for digital ulcers

Bei Xua Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P. R. ChinaView further author information
,
Ye Yua Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P. R. ChinaView further author information
,
Junyu Lianga Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P. R. ChinaView further author information
,
Guanhua Xua Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P. R. ChinaView further author information
,
Weiqian Chena Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P. R. ChinaView further author information
,
Jin Lina Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P. R. ChinaView further author information
&
Shenjiang Hub Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P. R. ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2276046 | Received 25 Jul 2023, Accepted 20 Oct 2023, Published online: 10 Dec 2023

References

  • Geyer M, Müller-Ladner U. The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol. 2011;40(2):1–4. doi: 10.1007/s12016-009-8193-3.
  • Varga J, Marangoni RG. Systemic sclerosis in 2016: dermal white adipose tissue implicated in SSc pathogenesis. Nat Rev Rheumatol. 2017;13(2):71–72. doi: 10.1038/nrrheum.2016.223.
  • Matucci-Cerinic M, Steen VD, Furst DE, et al. Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther. 2007;9(Suppl 2):S7. doi: 10.1186/ar2191.
  • Abraham DJ, Krieg T, Distler J, et al. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford). 2009;48(suppl_3):iii3–7. doi: 10.1093/rheumatology/ken481.
  • Manetti M, Guiducci S, Ibba-Manneschi L, et al. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med. 2010;14(6A):1241–1254. doi: 10.1111/j.1582-4934.2010.01027.x.
  • Hughes M, Herrick AL. Raynaud’s phenomenon. Best Pract Res Clin Rheumatol. 2016;30(1):112–132. doi: 10.1016/j.berh.2016.04.001.
  • Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology. 2017;56(1):14–25. doi: 10.1093/rheumatology/kew047.
  • Amanzi L, Braschi F, Fiori G, et al. Digital ulcers in scleroderma: staging, characteristics and Sub-setting through observation of 1614 digital lesions. Rheumatology 2010;49(7):1374–1382. doi: 10.1093/rheumatology/keq097.
  • Arefiev K, Fiorentino DF, Chung L. Endothelin receptor antagonis for the treatment of Raynaud’s phenomenon and digital ulcers in systemic sclerosis. Int J Rheumatol. 2011;2011:2017877. doi: 10.1155/2011/201787.
  • Hamaguchi Y, Sumida T, Kawaguchi Y, et al. Safety and tolerability of Bosetan for digital ulcers in Japanese patients with systemic sclerosis: prospective multicenter, open-label study. J Dermatol. 2017;44(1):13–17. doi: 10.1111/1346-8138.13497.
  • Chung L, Ball K, Yaqub A, et al. Effect of the endothelin type a selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic clerosis: results of a prospective pilot study. J Am Acad Dermatol. 2014;71(2):400–401. doi: 10.1016/j.jaad.2014.04.028.
  • Parisi S, Peroni CL, Laganà A, et al. Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminaty study. Rheumatology. 2013;52(6):1142–1144. doi: 10.1093/rheumatology/ket019.
  • Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–590. doi: 10.1002/art.1780230510.
  • Bose N, Bena J, Chatterjee S. Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial. Arthritis Res Ther. 2015;17(1):44. doi: 10.1186/s13075-015-0558-9.
  • Wei A, Gu Z, Li J, et al. Clinical adverse effects of endothelin receptor antagonists: insight from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J Am Heart Assoc. 2016;5:e003896.
  • Morrisroe K, Stevens W, Sahhar J, et al. Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. Arthritis Res Ther. 2019;21(1):299. doi: 10.1186/s13075-019-2080-y.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.